Velocity Nova Sp. z o.o.

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Obesity5 trials
• Type 2 diabetes3 trials
• Atrial fibrillation2 trials
• Heart failure2 trials
• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• Lupus (SLE)1 trial
• Stroke1 trial
• Type 1 diabetes1 trial

Phase

• Phase 312 trials
• Phase 22 trials

Status

• Active, not recruiting5 trials
• Recruiting4 trials
• Completed3 trials
• Not yet recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Novo Nordisk A/S5 trials
• Kailera2 trials
• Amgen Inc.1 trial
• Anthos Therapeutics, Inc.1 trial
• Boehringer Ingelheim1 trial
• and 4 more

Running trials

• Recruiting

  A study to test the safety and efficacy of RBD1119 given by injection in participants with coronary artery disease

  2026-525901-10-00· Phase 2· Ribocure Pharmaceuticals AB· Source

• Recruiting

  AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

  NCT07797335· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

  NCT07332481· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Active, not recruiting

  Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  NCT07284901· Phase 3· Kailera· Source

• Active, not recruiting

  Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  NCT07284875· Phase 3· Kailera· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

  2024-516652-18-00· Phase 3· Amgen Inc.· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

  NCT04755283· Phase 2· Anthos Therapeutics, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure2 recruiting
• Coronary artery disease1 recruiting
• Lupus (SLE)1 recruiting
• Obesity1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Withdrawn

  A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

  NCT07357766· Phase 3· Novo Nordisk A/S· Source

• Completed

  A study to evaluate the efficacy and safety of gliclazide MR in patients with type 2 diabetes inadequately controlled with dapagliflozin with or without metformin

  2024-511408-18-00· Phase 3· Institut De Recherches Internationales Servier IRIS· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

  NCT06323174· Phase 3· Novo Nordisk A/S· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source